CRISPR Therapeutics: The Technology that Edits Genes
CRISPR Therapeutics (NASDAQ: CRSP) is a biotechnology company leading the industry in the use of CRISPR gene editing. To give a simplified breakdown of what CRISPR/Cas9 gene editing technology is, it’s essentially a genetic engineering technique to modify and edit the genomes of a cell. This is relatively new technology as well as a huge breakthrough in the molecular biology community that can potentially transform the way we approach treatment of inherited genetic diseases as well as diseases from somatic mutations, such as cancer. This technique is significant not only due to the potential treatment possibilities, but highly low cost as highly precise. CRISPR Therapeutics is definitely worth looking into and here is why.
CRISPR Therapeutics is a leader in one of the most eye opening sectors within healthcare and conducts some of the most exciting studies in the industry. One recent study is centered around using the gene editing tool to reverse diabetes. They intend on engineering stem cells into immune invasive and insulin producing pancreatic cells, which have shown promising results thus far, already starting phase 2 of the study this February. Further results for this study can be expected later this year.
Just yesterday, CRISPR Therapeutics and Vertex Pharmaceuticals released two abstracts covering data of the ongoing CTXOO1 clinical trials, which have been accepted for presentation at the European Hematology Association 2021 Virtual Congress. The trial focuses on the use of CRISPR gene editing on patients with severe sickle cell disease or transfusion- dependent beta thalassemia.
What makes CRISPR Therapeutics and the CRISPR/Cas9 gene editing technique so revolutionary is that the potential is limitless. This technology can be applied to a wide array of diseases and can transform the treatment across diabetes, to cancer, to sickle cell disease, to other rare diseases. Unlike other treatment methods, genome editing does not simply fight a disease after its occured. Instead, it strives to completely erase the disease or even prevent it before it occurs.
Although still in the clinical stage, the company’s future looks promising. Current revenue of the company is not particularly impressive, but investors are more focused on the long term growth potential. CRSP has earned a buy rating across 21 firms, with a 1 year target price ranging from $161-$175. It closed trading at $101 as of May 13. Although not a penny stock, CRSP still shares the volatility of a clinical stage healthcare company. Much of the dip this year has been the market correcting itself and CRSP, which at one point was trading at a high in the $200s, was overvalued and subject to market correction.
Stock performance this year has been negative as it fell from trading highs in January and February, much like the stock market as a whole. Many investors are using the current market as an opportunity to buy. The company overall looks interesting, with clinical trials that could lead to the future of genetic disease treatment. So what are your thoughts? Leave them down below!